Dr Joanne Ngeow, MBBS, MRCP, MPH is Senior Consultant, Division of Medical Oncology at the National Cancer Centre Singapore and Associate Professor, Lee Kong Chian School of Medicine, Nanyang Technological University. Dr Ngeow currently heads the Cancer Genetics Service at the National Cancer Centre Singapore with an academic interest in hereditary cancer syndromes and translational clinical cancer genetics. She was awarded consecutive fellowships by the National Medical Research Council and the Ambrose Monell Foundation to complete formal clinical and bench training in Cancer Genomic Medicine at the Genomic Medicine Institute, Cleveland Clinic, Ohio. Dr Ngeow’s research focuses on understanding how a gene-environmental interaction predisposes to cancer initiation and progression. Her team seeks to identify, characterize and understand genes which cause susceptibility to traditional and complex heritable cancer syndromes, to determine their role in sporadic carcinogenesis. The Cancer Genetics Service led by Dr Ngeow is the go-to for clinical cancer genetics in Singapore and the region. Dr Ngeow is funded by the National Medical Research Council, Terry Fox Foundation and Lee Foundation. Her work is published in over 70 peer-reviewed top scientific journals and she is the recipient of consecutive scientific awards from the American Society of Clinical Oncology and Endocrine Society in recognition of her contributions to the field of cancer genomic medicine.

Dr. Shaheenah Dawood is a Consultant medical oncologist and associate professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the excellence In Oncology Care Congress that is held annually in Dubai and is co-president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and MENA immune-oncology summit.

One of Pune’s best breast cancer specialists and medical oncologist, Dr Shona Nag is known for her work in women’s health – especially breast cancer and cervical cancer. With over 27 years of practise, Dr Shona Nag, who studied medicine in Pune’s BJ Medical College, followed by an oncology fellowship at Tata Memorial Hospital in Mumbai, has made it her mission to encourage everyone to understand cancer better, particularly women.Currently the director, oncology at Sahayadri Group of Hospitals in Pune, Dr Shona Nag has been instrumental in helping patients navigate cancer better by also looking at pushing for new facilities and better care.

One of Pune’s best breast cancer specialists and medical oncologist, Dr Shona Nag is known for her work in women’s health – especially breast cancer and cervical cancer. With over 27 years of practise, Dr Shona Nag, who studied medicine in Pune’s BJ Medical College, followed by an oncology fellowship at Tata Memorial Hospital in Mumbai, has made it her mission to encourage everyone to understand cancer better, particularly women.Currently the director, oncology at Sahayadri Group of Hospitals in Pune, Dr Shona Nag has been instrumental in helping patients navigate cancer better by also looking at pushing for new facilities and better care.

Dr. Ghassan Abou-Alfa is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from American University of Beirut Faculty of Medicine and has been in practice 25 years. He also speaks multiple languages, including French and Arabic. He specializes in gastrointestinal cancer and is experienced in gastrointestinal oncology, general medical oncology, and liver cancer, biliary cancer, pancreatic cancer.

Dr Yip is currently a consultant breast surgeon in Ramsay Sime Darby Health Care in Malaysia, and is the lead clinician for the breast cancer research programme in Cancer Research Malaysia. Dr Yip was conferred Professor Emeritus by the University of Malaya in Oct 2016. She has over 220 publications in peer reviewed journals mainly on breast cancer in the Asian setting with an H index of 37. She was a past-president of the Association of University Surgeons of Asia (2003-2005) College of Surgeons of Malaysia (2010-2013) and Breast Surgery International (2015-2017). She is currently the President-Elect of International Surgical Society. Although a clinician, Dr Yip is very involved in cancer control and prevention, and was a past President of the Asia Pacific Organization for Cancer Prevention. (2010- 2012) She has been appointed an expert in cancer control by the World Health Organisation and has been on 2 IMPACT missions with the International Atomic Energy Agency (IAEA) to assess the cancer control program in Cambodia and Jordan. She has been involved with the Breast Health Global Initiative since 2005. She was awarded honorary fellowship from the American College of Surgeons in Oct 2013 and from the American Surgical Association in April 2017. She is currently an associate editor with World Journal of Surgery, academic editor of International Journal of Surgical Oncology, and on the international editorial board of JAMA Surgery. She is currently a member of the executive committee of Breast Cancer Welfare Association in charge of research and development.

Professor Ava Kwong is the Chief of Division of Breast Surgery, Daniel CK Yu Professor in Breast Cancer Research and Clinical Professor at The University of Hong Kong and The University of Hong Kong-Shenzhen Hospital. She founded Hong Kong Hereditary Breast Cancer Family Registry, where she serves as the Chairman

One of Pune’s best breast cancer specialists and medical oncologist, Dr Shona Nag is known for her work in women’s health – especially breast cancer and cervical cancer. With over 27 years of practise, Dr Shona Nag, who studied medicine in Pune’s BJ Medical College, followed by an oncology fellowship at Tata Memorial Hospital in Mumbai, has made it her mission to encourage everyone to understand cancer better, particularly women.Currently the director, oncology at Sahayadri Group of Hospitals in Pune, Dr Shona Nag has been instrumental in helping patients navigate cancer better by also looking at pushing for new facilities and better care.

Dr Yip is currently a consultant breast surgeon in Ramsay Sime Darby Health Care in Malaysia, and is the lead clinician for the breast cancer research programme in Cancer Research Malaysia. Dr Yip was conferred Professor Emeritus by the University of Malaya in Oct 2016. She has over 220 publications in peer reviewed journals mainly on breast cancer in the Asian setting with an H index of 37. She was a past-president of the Association of University Surgeons of Asia (2003-2005) College of Surgeons of Malaysia (2010-2013) and Breast Surgery International (2015-2017). She is currently the President-Elect of International Surgical Society. Although a clinician, Dr Yip is very involved in cancer control and prevention, and was a past President of the Asia Pacific Organization for Cancer Prevention. (2010- 2012) She has been appointed an expert in cancer control by the World Health Organisation and has been on 2 IMPACT missions with the International Atomic Energy Agency (IAEA) to assess the cancer control program in Cambodia and Jordan. She has been involved with the Breast Health Global Initiative since 2005. She was awarded honorary fellowship from the American College of Surgeons in Oct 2013 and from the American Surgical Association in April 2017. She is currently an associate editor with World Journal of Surgery, academic editor of International Journal of Surgical Oncology, and on the international editorial board of JAMA Surgery. She is currently a member of the executive committee of Breast Cancer Welfare Association in charge of research and development.

She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.

She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.

Janice Tsang is a Specialist in Medical Oncology and the Honorary Clinical Assistant Professor at the Li Ka Shing Faculty of Medicine, HKU, and Founding Convenor of HKBOG, Hong Kong. Dr Tsang’s research interests lie mainly in breast oncology, geriatric oncology, translational research and psycho-oncology. Being the first female academic medical oncologist at The University of Hong Kong (HKU), she was awarded the 2014 Hong Kong Ten Outstanding Young Persons Award, and the 2012 Hong Kong City Lady Award (Professional & Academic Category) as the only medical professional receiving this award for the year. She was also the winner of the Psychosocial Oncology Young Investigator Award at the 16th Hong Kong International Cancer Congress & 6th Annual Meeting of Centre for Cancer Research in 2009, and was bestowed the Faculty Teaching Medal in 2012, and the Outstanding Teaching Award (Team Award) for Medical Humanities in 2013 in recognition of her being one of the pioneers in incorporating medical humanities in the formal medical curriculum. She has conducted over 80 clinical trials, including local, regional and international multicenter clinical trials. She has been serving as Chairperson for the Data Monitoring Committee, Steering Committee members for major multi-centered clinical trials, as well as various international and regional advisory boards. She is a key opinion leader in breast oncology both locally and regionally. She is also the Founding Convenor of the HKBOG, which is now a member of the ‘Breast International Group’, being the 3rd Asian member after Japan and Taiwan. She is also appointed as Chair of the CTRG Audit Committee for the National Cancer Institute in 2017, and a member of the International Society of Geriatric Oncology (SIOG), serving as co-track chair for translational research in SIOG. She is also the Co-Chair of the Organizing Committee of the 8th Global Chinese Breast Cancer Organizations Alliance Conference 2021. Dr Tsang is currently member of the Specialty Board of Medical Oncology and used to be the Programme Director for Medical Oncology in the Hong Kong Island at the Hong Kong College of Physicians; a member of the Coordinating Committee (CoC) for Medical Oncology at the Hospital Authority; Deputy Chairperson for the Institutional Review Board for the Hong Kong West Cluster/HKU; and Director of Cancer Centre at Queen Mary Hospital, Hong Kong. She has various appointments in different professional bodies, such as Honorary Advisor for various cancer self-help groups, including the Hong Kong Christian Cancer Care Association and the Hong Kong Cancer Fund. Furthermore, she serves as member of the Social Welfare Advisory Committee and the Rehabilitation Advisory Committee in Hong Kong. She also serves as Deputy Chairman for the Women for Oncology Committee at the European Society of Medical Oncology (ESMO) for the term of 2020–2021, and as Founding Convenor of the Hong Kong Women for Oncology (HKW4O).

Dr. Obeid is an Assistant Professor in the Department of Clinical Genetics and Director of Breast, Ovary, and Prostate Cancer Risk Assessment Programs, as well as the Interim Chief of Breast Medical Oncology at Fox Chase Cancer Center. He attended medical school at the American University of Beirut School of Medicine, in Beirut, Lebanon and received a Master’s of Public Health degree from the University of Massachusetts. He completed his fellowship training in Medical Oncology and Hematology at the University of Chicago. Dr. Obeid focuses on the treatment of breast cancer, with particular interest in the treatment of triple-negative and hereditary breast cancers, as well as Breast, Ovary, and Prostate cancer risk assessment.

Dr Joanne Ngeow, MBBS, MRCP, MPH is Senior Consultant, Division of Medical Oncology at the National Cancer Centre Singapore and Associate Professor, Lee Kong Chian School of Medicine, Nanyang Technological University. Dr Ngeow currently heads the Cancer Genetics Service at the National Cancer Centre Singapore with an academic interest in hereditary cancer syndromes and translational clinical cancer genetics. She was awarded consecutive fellowships by the National Medical Research Council and the Ambrose Monell Foundation to complete formal clinical and bench training in Cancer Genomic Medicine at the Genomic Medicine Institute, Cleveland Clinic, Ohio. Dr Ngeow’s research focuses on understanding how a gene-environmental interaction predisposes to cancer initiation and progression. Her team seeks to identify, characterize and understand genes which cause susceptibility to traditional and complex heritable cancer syndromes, to determine their role in sporadic carcinogenesis. The Cancer Genetics Service led by Dr Ngeow is the go-to for clinical cancer genetics in Singapore and the region. Dr Ngeow is funded by the National Medical Research Council, Terry Fox Foundation and Lee Foundation. Her work is published in over 70 peer-reviewed top scientific journals and she is the recipient of consecutive scientific awards from the American Society of Clinical Oncology and Endocrine Society in recognition of her contributions to the field of cancer genomic medicine.

Dr. Christina Galvez is a medical oncologist with more than 10 years of practice in general oncology, primarily focusing in Breast Cancer. She finished her medical degree at the University of Santo Tomas and completed her formal training in medical oncology at the Veterans Memorial Medical Center -- both in Manila, Philippines. Her primary research interests include cancers of the Lung, Breast and Head and Neck, having been involved as principal investigator in several industry-sponsored clinical trials in key centers in the country. Dr. Galvez has been widely involved in oncology training programs and is currently a member of the Medical Oncology fellowship training committee at the St. Luke’s Medical Center – Global City (SLMC), Manila. Likewise, she is a member of the Philippine Specialty Board for Medical Oncology which is the primary body responsible for giving certifying examinations to graduates of oncology training programs in the country. Previously she has served as the President of the Philippine Breast Cancer Society and is currently a board member of the same organization. She has been involved in several Clinical Practice Guidelines committees in local institutions such as Philippine Society of Medical Oncology (PSMO) and SLMC. At present, she practices as an active consultant at SLMC, Taguig Medical Center and Veterans Memorial Medical Center. She has recently assumed the position of Assistant Head of the Cancer Institute at St. Luke’s.

Dr Joanne Ngeow, MBBS, MRCP, MPH is Senior Consultant, Division of Medical Oncology at the National Cancer Centre Singapore and Associate Professor, Lee Kong Chian School of Medicine, Nanyang Technological University. Dr Ngeow currently heads the Cancer Genetics Service at the National Cancer Centre Singapore with an academic interest in hereditary cancer syndromes and translational clinical cancer genetics. She was awarded consecutive fellowships by the National Medical Research Council and the Ambrose Monell Foundation to complete formal clinical and bench training in Cancer Genomic Medicine at the Genomic Medicine Institute, Cleveland Clinic, Ohio. Dr Ngeow’s research focuses on understanding how a gene-environmental interaction predisposes to cancer initiation and progression. Her team seeks to identify, characterize and understand genes which cause susceptibility to traditional and complex heritable cancer syndromes, to determine their role in sporadic carcinogenesis. The Cancer Genetics Service led by Dr Ngeow is the go-to for clinical cancer genetics in Singapore and the region. Dr Ngeow is funded by the National Medical Research Council, Terry Fox Foundation and Lee Foundation. Her work is published in over 70 peer-reviewed top scientific journals and she is the recipient of consecutive scientific awards from the American Society of Clinical Oncology and Endocrine Society in recognition of her contributions to the field of cancer genomic medicine.

She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.

Dr. Christina Galvez is a medical oncologist with more than 10 years of practice in general oncology, primarily focusing in Breast Cancer. She finished her medical degree at the University of Santo Tomas and completed her formal training in medical oncology at the Veterans Memorial Medical Center -- both in Manila, Philippines. Her primary research interests include cancers of the Lung, Breast and Head and Neck, having been involved as principal investigator in several industry-sponsored clinical trials in key centers in the country. Dr. Galvez has been widely involved in oncology training programs and is currently a member of the Medical Oncology fellowship training committee at the St. Luke’s Medical Center – Global City (SLMC), Manila. Likewise, she is a member of the Philippine Specialty Board for Medical Oncology which is the primary body responsible for giving certifying examinations to graduates of oncology training programs in the country. Previously she has served as the President of the Philippine Breast Cancer Society and is currently a board member of the same organization. She has been involved in several Clinical Practice Guidelines committees in local institutions such as Philippine Society of Medical Oncology (PSMO) and SLMC. At present, she practices as an active consultant at SLMC, Taguig Medical Center and Veterans Memorial Medical Center. She has recently assumed the position of Assistant Head of the Cancer Institute at St. Luke’s.

Dr Joanne Ngeow, MBBS, MRCP, MPH is Senior Consultant, Division of Medical Oncology at the National Cancer Centre Singapore and Associate Professor, Lee Kong Chian School of Medicine, Nanyang Technological University. Dr Ngeow currently heads the Cancer Genetics Service at the National Cancer Centre Singapore with an academic interest in hereditary cancer syndromes and translational clinical cancer genetics. She was awarded consecutive fellowships by the National Medical Research Council and the Ambrose Monell Foundation to complete formal clinical and bench training in Cancer Genomic Medicine at the Genomic Medicine Institute, Cleveland Clinic, Ohio. Dr Ngeow’s research focuses on understanding how a gene-environmental interaction predisposes to cancer initiation and progression. Her team seeks to identify, characterize and understand genes which cause susceptibility to traditional and complex heritable cancer syndromes, to determine their role in sporadic carcinogenesis. The Cancer Genetics Service led by Dr Ngeow is the go-to for clinical cancer genetics in Singapore and the region. Dr Ngeow is funded by the National Medical Research Council, Terry Fox Foundation and Lee Foundation. Her work is published in over 70 peer-reviewed top scientific journals and she is the recipient of consecutive scientific awards from the American Society of Clinical Oncology and Endocrine Society in recognition of her contributions to the field of cancer genomic medicine.

Dr. Christina Galvez is a medical oncologist with more than 10 years of practice in general oncology, primarily focusing in Breast Cancer. She finished her medical degree at the University of Santo Tomas and completed her formal training in medical oncology at the Veterans Memorial Medical Center -- both in Manila, Philippines. Her primary research interests include cancers of the Lung, Breast and Head and Neck, having been involved as principal investigator in several industry-sponsored clinical trials in key centers in the country. Dr. Galvez has been widely involved in oncology training programs and is currently a member of the Medical Oncology fellowship training committee at the St. Luke’s Medical Center – Global City (SLMC), Manila. Likewise, she is a member of the Philippine Specialty Board for Medical Oncology which is the primary body responsible for giving certifying examinations to graduates of oncology training programs in the country. Previously she has served as the President of the Philippine Breast Cancer Society and is currently a board member of the same organization. She has been involved in several Clinical Practice Guidelines committees in local institutions such as Philippine Society of Medical Oncology (PSMO) and SLMC. At present, she practices as an active consultant at SLMC, Taguig Medical Center and Veterans Memorial Medical Center. She has recently assumed the position of Assistant Head of the Cancer Institute at St. Luke’s.

Dr. Vasanti is a biochemist & molecular biologist. As a researcher, her interests were in studying intra-cellular signal transduction primarily through the cAMP/cGMP protein kinases & phoshodiesterases and the role they played in vascular modulation. She began working in pharmaceutical industry more than 20 years ago as she wanted to extend her scope to more applied research and drug development. During her time in pharma, She has held roles in early R&D, clinical development and medical affairs at regional and global levels. In the past 5 years, she has focussed on the application of precision medicine in oncology, particularly in the area of genomic profiling and the importance of integrating the inshights from such technologies in clinical practice. Her current role as VP global medical affairs at Caris Life sciences seeks to expand our footprint across larger territories, through education, evidence generation and medical support. Our hope is to engage and partner with more clinicians and thought leaders in our drive to bring next generation profiling into the clinic to help more patients

Dr Joanne Ngeow, MBBS, MRCP, MPH is Senior Consultant, Division of Medical Oncology at the National Cancer Centre Singapore and Associate Professor, Lee Kong Chian School of Medicine, Nanyang Technological University. Dr Ngeow currently heads the Cancer Genetics Service at the National Cancer Centre Singapore with an academic interest in hereditary cancer syndromes and translational clinical cancer genetics. She was awarded consecutive fellowships by the National Medical Research Council and the Ambrose Monell Foundation to complete formal clinical and bench training in Cancer Genomic Medicine at the Genomic Medicine Institute, Cleveland Clinic, Ohio. Dr Ngeow’s research focuses on understanding how a gene-environmental interaction predisposes to cancer initiation and progression. Her team seeks to identify, characterize and understand genes which cause susceptibility to traditional and complex heritable cancer syndromes, to determine their role in sporadic carcinogenesis. The Cancer Genetics Service led by Dr Ngeow is the go-to for clinical cancer genetics in Singapore and the region. Dr Ngeow is funded by the National Medical Research Council, Terry Fox Foundation and Lee Foundation. Her work is published in over 70 peer-reviewed top scientific journals and she is the recipient of consecutive scientific awards from the American Society of Clinical Oncology and Endocrine Society in recognition of her contributions to the field of cancer genomic medicine.

Dr. Christina Galvez is a medical oncologist with more than 10 years of practice in general oncology, primarily focusing in Breast Cancer. She finished her medical degree at the University of Santo Tomas and completed her formal training in medical oncology at the Veterans Memorial Medical Center -- both in Manila, Philippines. Her primary research interests include cancers of the Lung, Breast and Head and Neck, having been involved as principal investigator in several industry-sponsored clinical trials in key centers in the country. Dr. Galvez has been widely involved in oncology training programs and is currently a member of the Medical Oncology fellowship training committee at the St. Luke’s Medical Center – Global City (SLMC), Manila. Likewise, she is a member of the Philippine Specialty Board for Medical Oncology which is the primary body responsible for giving certifying examinations to graduates of oncology training programs in the country. Previously she has served as the President of the Philippine Breast Cancer Society and is currently a board member of the same organization. She has been involved in several Clinical Practice Guidelines committees in local institutions such as Philippine Society of Medical Oncology (PSMO) and SLMC. At present, she practices as an active consultant at SLMC, Taguig Medical Center and Veterans Memorial Medical Center. She has recently assumed the position of Assistant Head of the Cancer Institute at St. Luke’s.

Dr See Hui Ti is a medical oncologist at Mount Elizabeth Hospitals and Gleneagles Hospital, Singapore. Having registered with the General Medical Council in the UK in 1996, Dr See worked at the Queen Elizabeth Hospital in Birmingham, UK, before continuing her internal medicine training at the Singapore General Hospital. Dr See was awarded the HMDP fellowship in 2002 after completing advanced oncology training at the National Cancer Centre.

Dr See Hui Ti is a medical oncologist at Mount Elizabeth Hospitals and Gleneagles Hospital, Singapore. Having registered with the General Medical Council in the UK in 1996, Dr See worked at the Queen Elizabeth Hospital in Birmingham, UK, before continuing her internal medicine training at the Singapore General Hospital. Dr See was awarded the HMDP fellowship in 2002 after completing advanced oncology training at the National Cancer Centre.

Prof. Büttner is Professor and Chairman for Pathology at the University of Cologne; and Director of the Institute for General Pathology and Pathological Anatomy at the University Hospital of Cologne. He is also CSO and Co-Founder of Targos Molecular Pathology. A pathologist with authorship on over 600 publications, Prof. Büttner’s areas of research in NSCLC include: diagnostic and predictive genomics, biomarker testing, mutation screening, and mutation targeted precision therapies. Since 2009, Prof. Büttner has served as an Executive Board Member of the Mildred Scheel Foundation for Cancer Research, and as Executive Board Director of the Vladimir Totovic Foundation. He also holds memberships with the German Society of Pathology, and the International Academy of Pathology.

Dr See Hui Ti is a medical oncologist at Mount Elizabeth Hospitals and Gleneagles Hospital, Singapore. Having registered with the General Medical Council in the UK in 1996, Dr See worked at the Queen Elizabeth Hospital in Birmingham, UK, before continuing her internal medicine training at the Singapore General Hospital. Dr See was awarded the HMDP fellowship in 2002 after completing advanced oncology training at the National Cancer Centre.

Frederik Marmé is currently Professor of Gynecology for the Medical Faculty of Mannheim at the University of Heidelberg in Germany. Professor Marmé studied in Freiburg, Heidelberg and London and obtained his medical degree in 2002 from the University of Heidelberg Medical School. From 2002 to 2003, he worked as a post-doctoral researcher at the German Cancer Research Centre (DKFZ) in Heidelberg in the Department of Growth Control and Signal Transduction. Professor Marmé completed his residency in Obstetrics and Gynaecology at the University Hospital Heidelberg from 2003 to 2004 and received his doctoral degree in 2005 for his work on tetracyclin-controlled inducible eucaryotic expression systems, which he performed at the Centre for Molecular Biology at the University of Heidelberg (ZMBH) in the laboratory of Prof. Hermann Bujard. He held a fellowship in obstetrics and gynaecology, gynaecological oncology, and breast oncology at the University Hospital Heidelberg from 2004 to 2010, completing a second post-doctoral research post at the German Cancer Research Centre from 2006 to 2007 in the Department of Molecular Genetics on the topic of predictive and prognostic factors in early breast cancer. He earned his board certificate in Obstetrics and Gynaecology in 2010 and served as a consultant in gynaecology and breast oncology at the National Centre for Tumor Diseases (NCT) in Heidelberg from 2010 to 2019. In 2019 Professor Marmé accepted a position as Professor for Experimental and Translational Gynaecologic Oncology at the Medical Faculty Mannheim of the Heidelberg University. He is also the Head of the Clinical Trials Unit at the Department of Gynaecologic Oncology of the University Hospital Mannheim. He is an elected member of the German Breast Group (GBG), the executive Board of the AGO-study group, and an AGO study group representative for the ENGOT early drug development group. He serves as a member of the faculty of the European Society of Medical Oncology (ESMO) and as an associate editor of “Cancer Investigations”. He also belongs to several clinical & scientific societies, including the European Society of Medical Oncology (ESMO), the German Society of Hematology & Oncology (DGHO), the European Society of Gynecologic Oncology (ESGO) and the German Society of Obstetrics and Gynecology (DGGG). Professor Marmé is actively involved in clinical research, having served as the principal investigator for over 35 studies and as a co-principal investigator on nearly 50 others since 2004. His research interests include translational research, predictive and prognostic biomarkers, molecular profiling, and immunotherapies in breast and ovarian cancer. He has co-authored over 130 peer-reviewed journal articles.

Dr See Hui Ti is a medical oncologist at Mount Elizabeth Hospitals and Gleneagles Hospital, Singapore. Having registered with the General Medical Council in the UK in 1996, Dr See worked at the Queen Elizabeth Hospital in Birmingham, UK, before continuing her internal medicine training at the Singapore General Hospital. Dr See was awarded the HMDP fellowship in 2002 after completing advanced oncology training at the National Cancer Centre.

Prof. Büttner is Professor and Chairman for Pathology at the University of Cologne; and Director of the Institute for General Pathology and Pathological Anatomy at the University Hospital of Cologne. He is also CSO and Co-Founder of Targos Molecular Pathology. A pathologist with authorship on over 600 publications, Prof. Büttner’s areas of research in NSCLC include: diagnostic and predictive genomics, biomarker testing, mutation screening, and mutation targeted precision therapies. Since 2009, Prof. Büttner has served as an Executive Board Member of the Mildred Scheel Foundation for Cancer Research, and as Executive Board Director of the Vladimir Totovic Foundation. He also holds memberships with the German Society of Pathology, and the International Academy of Pathology.

Frederik Marmé is currently Professor of Gynecology for the Medical Faculty of Mannheim at the University of Heidelberg in Germany. Professor Marmé studied in Freiburg, Heidelberg and London and obtained his medical degree in 2002 from the University of Heidelberg Medical School. From 2002 to 2003, he worked as a post-doctoral researcher at the German Cancer Research Centre (DKFZ) in Heidelberg in the Department of Growth Control and Signal Transduction. Professor Marmé completed his residency in Obstetrics and Gynaecology at the University Hospital Heidelberg from 2003 to 2004 and received his doctoral degree in 2005 for his work on tetracyclin-controlled inducible eucaryotic expression systems, which he performed at the Centre for Molecular Biology at the University of Heidelberg (ZMBH) in the laboratory of Prof. Hermann Bujard. He held a fellowship in obstetrics and gynaecology, gynaecological oncology, and breast oncology at the University Hospital Heidelberg from 2004 to 2010, completing a second post-doctoral research post at the German Cancer Research Centre from 2006 to 2007 in the Department of Molecular Genetics on the topic of predictive and prognostic factors in early breast cancer. He earned his board certificate in Obstetrics and Gynaecology in 2010 and served as a consultant in gynaecology and breast oncology at the National Centre for Tumor Diseases (NCT) in Heidelberg from 2010 to 2019. In 2019 Professor Marmé accepted a position as Professor for Experimental and Translational Gynaecologic Oncology at the Medical Faculty Mannheim of the Heidelberg University. He is also the Head of the Clinical Trials Unit at the Department of Gynaecologic Oncology of the University Hospital Mannheim. He is an elected member of the German Breast Group (GBG), the executive Board of the AGO-study group, and an AGO study group representative for the ENGOT early drug development group. He serves as a member of the faculty of the European Society of Medical Oncology (ESMO) and as an associate editor of “Cancer Investigations”. He also belongs to several clinical & scientific societies, including the European Society of Medical Oncology (ESMO), the German Society of Hematology & Oncology (DGHO), the European Society of Gynecologic Oncology (ESGO) and the German Society of Obstetrics and Gynecology (DGGG). Professor Marmé is actively involved in clinical research, having served as the principal investigator for over 35 studies and as a co-principal investigator on nearly 50 others since 2004. His research interests include translational research, predictive and prognostic biomarkers, molecular profiling, and immunotherapies in breast and ovarian cancer. He has co-authored over 130 peer-reviewed journal articles.

Dr. Karmen Wong is a medical oncologist with over than 20 years of clinical practice. She received her oncology training in the National University Hospital (NUH), National Cancer Centre, Singapore (NCC) and University of California, San Francisco (UCSF), who have a reputation for health sciences research and patient care under the HMDP scholarship.She helped establish the first multi-disciplinary breast cancer treatment in Singapore 20 years ago in NCC, which created a platform for treatment in other cancer types with doctors of different disciplines. Dr Wong also initiated the bone marrow transplant programme in solid tumour in Singapore General Hospital (SGH) in 1997.

Mark Robson, MD, is an Associate Attending Physician of the Clinical Genetics and Breast Medicine Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center. He received his B.Sc. from Washington and Lee University and his MD from the University of Virginia. He performed residency and fellowship training at Walter Reed Army Medical center before coming to Memorial Sloan Kettering in 1996. He is currently the Clinic Director of the Clinical Genetics Service and the chair of the Cancer Genetics Subcommittee of the American Society of Clinical Oncology. Dr. Robson's research is directed toward the improving the integration of genetic information into the clinical management of women with breast cancer. He and his colleagues have conducted a number of studies examining outcomes in women with hereditary breast cancer to better define the risks and benefits of treatments such as breast conserving therapy and adjuvant chemotherapy in this group. He and his coworkers have also conducted a number of studies examining the effectiveness of screening interventions such as breast MRI or ovarian cancer screening in women at hereditary risk. He is currently conducting studies to evaluate the impact of intensive screening or surgical prevention upon women's quality of life, and to develop new screening tools, such as serum peptide profiling.

Dr Mastura Md Yusof is currently the Resident Consultant Oncologist for the Cancer Institute of Pantai Hospital Lumpur. Her area of expertise in clinical oncology encompasses radiotherapy and Medical Oncology as well as clinical research in various cancer types or sites. Dr Mastura serves as consultant in various advisory boards and expert committee panels for cancer and cancer-related services in government such as good oncology practice and chemotherapy protocol guideline, as well as in private sectors. She has worked and shared her expertise with NGOs championing cancer awareness, early diagnosis and treatment within Malaysia and South East Asia.

Dr. Obeid is an Assistant Professor in the Department of Clinical Genetics and Director of Breast, Ovary, and Prostate Cancer Risk Assessment Programs, as well as the Interim Chief of Breast Medical Oncology at Fox Chase Cancer Center. He attended medical school at the American University of Beirut School of Medicine, in Beirut, Lebanon and received a Master’s of Public Health degree from the University of Massachusetts. He completed his fellowship training in Medical Oncology and Hematology at the University of Chicago. Dr. Obeid focuses on the treatment of breast cancer, with particular interest in the treatment of triple-negative and hereditary breast cancers, as well as Breast, Ovary, and Prostate cancer risk assessment.

She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.

Omal Khair is currently a Consultant in the Division of Adult Medical, Department of Oncology in Ministry of National Guard Health Affairs – Saudi Arabia and Assistant Professor at the King Saud bin Abdulaziz University for Health Sciences.

One of Pune’s best breast cancer specialists and medical oncologist, Dr Shona Nag is known for her work in women’s health – especially breast cancer and cervical cancer. With over 27 years of practise, Dr Shona Nag, who studied medicine in Pune’s BJ Medical College, followed by an oncology fellowship at Tata Memorial Hospital in Mumbai, has made it her mission to encourage everyone to understand cancer better, particularly women.Currently the director, oncology at Sahayadri Group of Hospitals in Pune, Dr Shona Nag has been instrumental in helping patients navigate cancer better by also looking at pushing for new facilities and better care.

.

Dr. Bhawna Sirohi started her oncology career at Tata Memorial centre (TMC), Mumbai in 1994 and completed training at Royal Marsden NHS Foundation Trust, UK. She serves in Apollo Hospital and is currently an honorary consultant with QMUL, London. At TMC in 2012-2014, she set up GI medical oncology &medical oncology information system (MOIS) for e-prescribing chemotherapy. She has been involved in initial setting up of cancer centres in Sangrur and Mohali, Punjab for TMC. She has piloted use of virtual consults using PROM & PREM in London.

Dr Tira Tan is a consultant medical oncologist at the National Cancer Centre Singapore with a clinical focus in the treatment of breast cancers and early phase drug development. Dr Tan chairs the pre-operative and young women’s breast cancer programs at NCCS and is the primary and co-investigator on many early and late phase studies specifically in novel therapeutics and treatment strategies in triple negative breast cancer.

Dr Elaine Lim is Senior Consultant, Division of Medical Oncology at the National Cancer Centre, Singapore. Her interests are centred on breast, gynaecological and lung cancers. After graduating from Trinity College, University of Cambridge, Dr. Lim was selected to join the Cambridge MBBCh-PhD programme. Her PhD dissertation on molecular genetics was supervised by Nobel Laureate, Professor Sydney Brenner and Professor Timothy Cox. After completing her clinical training in Cambridge, Dr. Lim worked in London, which included the Royal London Hospital and the prestigious London ‘golden circuit’ of Hammersmith Hospital and Royal Brompton Hospital. Upon her return to Singapore, she joined the National University of Singapore (NUS) and National University Hospital (NUH) to pursue a career in Medical Oncology. She later moved to Johns Hopkins Singapore as Consultant in Medical Oncology, as well as being Visiting Consultant at Tan Tock Seng Hospital (TTSH) and Kandang Kerbau Women’s and Children’s Hospital (KKH). After a few years in private practice with Singapore Oncology Consultants, she joined the National Cancer Centre, Singapore, Division of Medical Oncology. She has continued her laboratory research activities in collaboration with the Genome Institute of Singapore and the Institute of Molecular and Cell Biology, and actively participates in clinical trials.

Dr Mastura Md Yusof is currently the Resident Consultant Oncologist for the Cancer Institute of Pantai Hospital Lumpur. Her area of expertise in clinical oncology encompasses radiotherapy and Medical Oncology as well as clinical research in various cancer types or sites. Dr Mastura serves as consultant in various advisory boards and expert committee panels for cancer and cancer-related services in government such as good oncology practice and chemotherapy protocol guideline, as well as in private sectors. She has worked and shared her expertise with NGOs championing cancer awareness, early diagnosis and treatment within Malaysia and South East Asia.

Dr. John Chia is a medical oncologist practicing at Mount Elizabeth Novena Hospital, Singapore. His subspeciality interests include ovarian, endometrial, cervical, breast and colorectal cancers, as well as the management of rare tumours such as melanoma, uterine sarcoma, and germ cell tumours. He sits on the scientific board of the International Aspirin Foundation, and lectures widely, in Japan, Korea, HK, China and UK, as well as plenary symposia lectures in Germany, Australia and ESMO Asia. He is also a consultant at several biotechnology and pharmaceutical companies, advising the development of novel therapeutics and immunotherapy for cancer. Dr Chia sits on the Singapore Cancer Society’s Women’s Gynaecological Cancer Awareness Committee, and has helped to write the Singapore ovarian and uterine cancer management guidelines (SCAN). He also sits on the executive committee of the Singapore Society of Oncology (SSO) and their Cancer Immunotherapy Consortium, aiming to promote access, recruitment, and immune monitoring and toxicity management for patients on immunotherapeutic treatments in Singapore.

Ma. Pamela D. Patdu, MD is a graduate of the University of the Philippines College of Medicine. She had her Internal Medicine and Medical Oncology training in the University of the Philippines-Philippine General Hospital. She is presently head of the Philippine Society of Medical Oncology's Clinical Practice Guidelines Committee.

Dr. Valerie Heong is a medical oncologist at Tan Tock Seng Hospital. She received her medical degree from the University of Adelaide, Australia and subsequently trained in medical oncology in Melbourne, Australia. She obtained her PhD in Molecular Biology from the Department of Medical Biology, University of Melbourne, Australia. During her PhD she was awarded the Ovarian Cancer Australia Postgraduate Scholarship and the Bev Gray Ovarian Cancer PhD Scholarship. She subsequently moved to Singapore as a clinician scientist with a special interest in breast and gynaecological malignancies, drug development and cancer genetics research. Her research focuses on development of novel therapeutic agents and biomarker discovery in breast and ovarian cancer. She was awarded the Helene Harris Memorial Trust (HHMT) Fellowship Award, The Yong Siew Yoon fellowship award and the LKC Clinician Scientist Career Scheme award for her research which aims to identify aberrant molecular pathways in breast and ovarian cancer that may potentially be exploited and targeted for therapeutic development to improve patient outcomes.

Dr Tse is Clinical Associate Professor in the Department of Obstetrics and Gynaecology at The University of Hong Kong, and honorary consultant of the Queen Mary Hospital and HKU-Shenzhen Hospital. She received her gynaecological oncology training in Hong Kong and Cambridge, United Kingdom. Her research interests include gynaecological cancer biology and novel treatments in recurrent and advanced gynaecological malignancies. Dr Tse is an editorial member of the Hong Kong Medical Journal and guest editor of Frontiers in Oncology. She is the secretary of the Obstetrical and Gynaecological Society of Hong Kong, the chairman of the colposcopy sub-committee and member of the gynaecological oncology sub-committee of the Hong Kong College of Obstetrics and Gynaecology. She is also a board member of the Asian Society for Gynecological Robotic Surgery (ASGRS), board member of the Asian Gynecologic Oncology Group (AGOG), and secretary of the Gynaecological Oncology committee, Asia & Oceania Federation of Obstetrics & Gynaecology (AOFOG).

Prof. Mokhtar completed a B.Sc. in medicine and then a M.Sc. in Clinical Oncology at the Cairo University Kasr El Aini Medical School graduating in 1991 and 1996 respectively. In 2001 he completed his MD training in clinical oncology, also at the Cairo University Kasr El Aini Medical School. Since 1996 he has held a number of posts at the Cairo University Kasr El Aini Medical School where he primarily and currently undertook clinical research, supervising numerous research programs, and developed critical teaching material. Since 2001 he has held the position of Professor of Clinical Oncology. He has many publications in regional magazines in topics including, breast, lung, paediatric, colorectal and ovarian malignancies, NHL and hematologic malignancies. He collaborates in several trials,both regional and international, and is a scientific co-ordinator for many regional and international conferences. Prof.Mokhtar has been a speaker at conferences, both regional and international, including PAN ARAB, EURO-Mediterranean conferences and EASO classes at theKasr El Aini School of Oncology. Prof. Ibrahim is also an active member of the Arab Medical Association Against Cancer(AMAAC), the Egyptian Cancer society(ECS) and the Egyptian Hemato-oncology Group (EHOG).

Ma. Pamela D. Patdu, MD is a graduate of the University of the Philippines College of Medicine. She had her Internal Medicine and Medical Oncology training in the University of the Philippines-Philippine General Hospital. She is presently head of the Philippine Society of Medical Oncology's Clinical Practice Guidelines Committee.

Dr Jack Chan is a Consultant Medical Oncologist practising at National Cancer Centre Singapore (NCCS) and KK Women’s and Children’s Hospital, Singapore. His subspecialty interests are gynaecological cancers and breast cancer. A Clinical Assistant Professor at Duke-NUS Medical School, his research interests include early and late phase clinical trials and translational work in gynaecological and breast cancers. He is the Principal Investigator of investigator-initiated and industry-sponsored trials at NCCS. Dr Chan is also active in medical education as well as in professional societies such as the Gynecological Cancer Group Singapore and College of Physicians, Academy of Medicine, Singapore.

Dr. Valerie Heong is a medical oncologist at Tan Tock Seng Hospital. She received her medical degree from the University of Adelaide, Australia and subsequently trained in medical oncology in Melbourne, Australia. She obtained her PhD in Molecular Biology from the Department of Medical Biology, University of Melbourne, Australia. During her PhD she was awarded the Ovarian Cancer Australia Postgraduate Scholarship and the Bev Gray Ovarian Cancer PhD Scholarship. She subsequently moved to Singapore as a clinician scientist with a special interest in breast and gynaecological malignancies, drug development and cancer genetics research. Her research focuses on development of novel therapeutic agents and biomarker discovery in breast and ovarian cancer. She was awarded the Helene Harris Memorial Trust (HHMT) Fellowship Award, The Yong Siew Yoon fellowship award and the LKC Clinician Scientist Career Scheme award for her research which aims to identify aberrant molecular pathways in breast and ovarian cancer that may potentially be exploited and targeted for therapeutic development to improve patient outcomes.

Dr. Golan is a highly qualified medical oncologist and researcher in the field of pancreatic cancer. She specializes in gastrointestinal malignancies, and serves as a director of the Phase I clinical trials unit at Sheba’s Pancreatic Cancer Center. She has earned a world-renowned reputation for her studies in the field of pancreatic cancer. Her current research trials to test new medicine therapies for metastatic pancreatic cancer are being carried out in conjunction with two of the world’s largest biopharmaceutical companies, AstraZeneca and MSD (Merck). Dr. Golan’s research offers new hope for patients worldwide with pancreatic cancer, particularly pancreatic adenocarcinoma harboring BRCA mutations. In the clinical trial, more than 3,000 patients were screened, and of them, 154 were randomized and assigned a trial intervention. The results showed that patients who received the POLO trial’s drug treatment did significantly better overall than those who did not receive the drug.

Dr Chiang Jianbang is an Associate Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS). He focuses on cancer genetics in NCCS and works with a team of dedicated geneticist and genetic counsellors. He hopes to empower patients, family members and healthcare professionals with cancer genetics knowledge to improve personal and public health. His interests are in clinical cancer genetics, genomic medicine and implementation science.

Dr Joycelyn Lee graduated from National University of Singapore and completed her post-graduate training in Medical Oncology at National Cancer Centre Singapore. Her clinical and research interests are in gastrointestinal malignancies, particularly hepatopancreatobiliary cancers and immuno-oncology.

Dr. Nitesh Rohatgi is a senior consultant in Medical Oncology at Max Hospital in Saket, who was till recently working at the prestigious London Oncology Clinic (Leaders in Oncology care), Harley Street, London. He is a fellow of the Royal Society of medicine and has much publication to his name. He was trained in medical oncology, palliative medicine and teenage young adult’s cancers in United Kingdom, completing his CCT in 2009.

Dr. Golan is a highly qualified medical oncologist and researcher in the field of pancreatic cancer. She specializes in gastrointestinal malignancies, and serves as a director of the Phase I clinical trials unit at Sheba’s Pancreatic Cancer Center. She has earned a world-renowned reputation for her studies in the field of pancreatic cancer. Her current research trials to test new medicine therapies for metastatic pancreatic cancer are being carried out in conjunction with two of the world’s largest biopharmaceutical companies, AstraZeneca and MSD (Merck). Dr. Golan’s research offers new hope for patients worldwide with pancreatic cancer, particularly pancreatic adenocarcinoma harboring BRCA mutations. In the clinical trial, more than 3,000 patients were screened, and of them, 154 were randomized and assigned a trial intervention. The results showed that patients who received the POLO trial’s drug treatment did significantly better overall than those who did not receive the drug.

Dr. Bhawna Sirohi started her oncology career at Tata Memorial centre (TMC), Mumbai in 1994 and completed training at Royal Marsden NHS Foundation Trust, UK. She serves in Apollo Hospital and is currently an honorary consultant with QMUL, London. At TMC in 2012-2014, she set up GI medical oncology &medical oncology information system (MOIS) for e-prescribing chemotherapy. She has been involved in initial setting up of cancer centres in Sangrur and Mohali, Punjab for TMC. She has piloted use of virtual consults using PROM & PREM in London.

Dr Chiang Jianbang is an Associate Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS). He focuses on cancer genetics in NCCS and works with a team of dedicated geneticist and genetic counsellors. He hopes to empower patients, family members and healthcare professionals with cancer genetics knowledge to improve personal and public health. His interests are in clinical cancer genetics, genomic medicine and implementation science.

Dr Joycelyn Lee graduated from National University of Singapore and completed her post-graduate training in Medical Oncology at National Cancer Centre Singapore. Her clinical and research interests are in gastrointestinal malignancies, particularly hepatopancreatobiliary cancers and immuno-oncology.

Dr. Choo Su Pin is a medical oncologist who specializes in gastrointestinal cancers including colorectal, upper gastrointestinal, pancreas, hepatobiliary, peritoneal, and anal cancers. Dr. Choo is the immediate past president of the Singapore Society of Oncology, a founding member of the SSO- Cancer Immunotherapy Consortium and a council member of the Chapter of Medical Oncology, Academy of Medicine, Singapore. She is currently an expert panel member of HCC Connect which develops educational programmes for healthcare professionals around the world in liver oncology.

Assoc Prof. Ravindran Kanesvaran is a Deputy Head and Senior Consultant in the Department of Medical Oncology of the National Cancer Centre Singapore. He is also an Associate Professor at Duke-NUS Graduate Medical School and clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He is actively involved in graduate medical education and is the Program Director of the Medical Oncology Senior Residency Program. His research interests include GU oncology and geriatric oncology. He has published in a number of well-known peer reviewed journals including Journal of Clinical Oncology and Lancet Oncology. He is the author of several textbook chapters in Geriatric Oncology. He has also been awarded a number of awards including the American Society of Clinical Oncology (ASCO GU) Merit Award 2009, American Association for Cancer Research (AACR) scholar-in-training Award 2010 and European Society of Medical Oncology (ESMO) fellowship award 2012. He is currently the Immediate Past President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He had been appointed as European Society of Medical Oncology (ESMO) Faculty 2015-2016 in Geriatric Oncology and 2016-2020 in GU Oncology. He was the host and steering committee member of the first ESMO Asia meeting in 2015 and is currently on the ESMO Council as well. He is President-Elect and the National Representative for Singapore in the International Society of Geriatric Oncology (SIOG). He is also the Vice Chairman of the Singapore Cancer Society (SCS).

Dr Darren Ming-Chun Poon is the Honorary Clinical Associate Professor at the Chinese University of Hong Kong and the Honorary Consultant in Clinical Oncology at both the Hong Kong Sanatorium & Hospital and Prince of Wales Hospital, Hong Kong. Dr Poon has several specialist areas of expertise, which include genitourinary (GU) cancer, neuro-oncology, hepato-pancreatic cancer, and head and neck cancer. His research interests include novel therapies for GU cancers, image-guided radiotherapy and stereotactic body radiotherapy (SBRT) for prostate, central nervous system tumor, pancreatic and liver cancer. Dr Poon pioneered the use of SBRT in the treatment of prostate cancer in Hong Kong and completed the first-in-Asia randomized study for prostate SBRT. He has published more than 50 original papers, scientific reviews, and abstracts in peer-reviewed journals and has co-authored the 10th edition of Fast Facts: Prostate Cancer. He is one of the expert panel members in the Advanced Prostate Cancer Consensus Conference (APCCC) from 2019 onwards, and the Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC-APCCC) from 2020 onwards. Dr Poon has been an invited speaker at local and regional, and international conferences and is currently involved in several clinical trials investigating new therapies for urothelial, bladder, renal and prostate cancers. In addition to his clinical and academic duties, Dr Poon has been Vice-President of several professional societies, including the Hong Kong Society of Uro-Oncology, Hong Kong Nasopharyngeal Carcinoma Study Group and the Hong Kong SBRT study group. In addition, he is a Council Member of the Hong Kong Prostate Foundation and Vice-Chairman of the Hand in Hand Cancer Foundation.

Assoc Prof. Ravindran Kanesvaran is a Deputy Head and Senior Consultant in the Department of Medical Oncology of the National Cancer Centre Singapore. He is also an Associate Professor at Duke-NUS Graduate Medical School and clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He is actively involved in graduate medical education and is the Program Director of the Medical Oncology Senior Residency Program. His research interests include GU oncology and geriatric oncology. He has published in a number of well-known peer reviewed journals including Journal of Clinical Oncology and Lancet Oncology. He is the author of several textbook chapters in Geriatric Oncology. He has also been awarded a number of awards including the American Society of Clinical Oncology (ASCO GU) Merit Award 2009, American Association for Cancer Research (AACR) scholar-in-training Award 2010 and European Society of Medical Oncology (ESMO) fellowship award 2012. He is currently the Immediate Past President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He had been appointed as European Society of Medical Oncology (ESMO) Faculty 2015-2016 in Geriatric Oncology and 2016-2020 in GU Oncology. He was the host and steering committee member of the first ESMO Asia meeting in 2015 and is currently on the ESMO Council as well. He is President-Elect and the National Representative for Singapore in the International Society of Geriatric Oncology (SIOG). He is also the Vice Chairman of the Singapore Cancer Society (SCS).

Dr. Kumar is Professor, Medical Oncology at Tata Memorial Hospital and has more than two decades of experience. He has published over a hundred research and review articles/papers in journals of national and international repute.He has undertaken over 80 projects as Principal Ivestigator and Co-Investigator.He is a member of many international and national scientific societies and associations and has delivered talks in several conferences.

Dr. Jae Young Joung is working in Center for Prostate Cancer as Faculty of Medicine in National Cancer Center, Goyang, Korea. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in his wide range of publications in various national and international journals.

Dr Johan Chan is an Associate Consultant in the Divison of Medical Oncology of the National Cancer Centre Singapore. He completed his medical oncology specialty training in Australia. As part of his specialist training, he completed a fellowship in National Cancer Centre Singapore and continued practising as an Associate Consultant. His research interest includes GU oncology and Geriatric oncology.

Dr Tanujaa Rajasekaran is a Consultant in the Department of Medical Oncology of the National Cancer Centre Singapore, sub-specializing in genitourinary and thoracic and cancers. She graduated from the National University of Singapore and was awarded the Dean’s list during her undergraduate studies. She completed her medical oncology specialty training in the National Cancer Centre Singapore. Her research interests are in geriatric oncology and genitourinary cancers. She also awarded the European Society of Medical Oncology (ESMO) fellowship grant 2013 for her research in geriatric oncology. She has published in a number of well-known peer reviewed journals including Journal of Clinical Oncology. She is also actively involved in medical education. She is a Clinical Assistant Professor with Duke NUS medical school. She is also a core faculty member of the Medical Oncology Senior Residency Program and Clinical Lecturer in Yong Loo Lin School of Medicine, NUS.

Dr Melvin Chua is a Clinician-Scientist at the National Cancer Centre Singapore, and Principal Investigator of the Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Beam Therapy – Precision Radiation Oncology Programme, He is also the Head of Department and Senior Consultant of Head and Neck and Thoracic Cancers, Division of Radiation Oncology. His research is supported by the NMRC Clinician-scientist award, and is focused on discovery and translational cancer genomics, and the development of biomarker-directed clinical trials in nasopharyngeal (NPC) and prostate cancers. He graduated from the Yong Loo Lin School of Medicine, National University Singapore in 2002. He obtained his Fellowship in Clinical Oncology from the Royal College of Radiologists, and his Doctorate from the University College London in 2013. He later completed post-doctoral Clinician-scientist fellowships at the Mount Vernon Cancer Centre, UK, and the Princess Margaret Cancer Center, Toronto. Dr Chua is a KOL on NPC and prostate cancer, and he has been invited to speak at more than 100 international meetings. He is also on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network, a board member on the Head Neck Cancer International Group (HNCIG) and the Scientific Committee Chair of HNCIG Artificial Intelligence working group. His other academic activities include his roles as the Associate Senior Editor of the International Journal of Radiation Oncology Biology Physics – Official journal of the American Society of Radiation Oncology and Editor-in-Chief, Annals of Nasopharynx Cancer. He also serves on the International Education Steering Group and the Asia-Pacific Regional Council of the American Society of Clinical Oncology (ASCO). He has published over 100 peer-reviewed papers, with a H-index of 27, including highly cited articles in the New England Journal of Medicine, Lancet, Nature, Cell, Journal of Clinical Oncology and JAMA Oncology.

Dr. Shaheenah Dawood is a Consultant medical oncologist and associate professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the excellence In Oncology Care Congress that is held annually in Dubai and is co-president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and MENA immune-oncology summit.